10-Q: Bone Biologics Boosts Cash, Advances Clinical Trial

Bone Biologics Corporation reported increased cash reserves and progress in its clinical trials, despite continued net losses and ongoing going concern doubts.

Summary

• Net loss for the six months ended June 30, 2025, was $1,757,611, an increase from $1,649,703 for the same period in 2024.
• Cash and cash equivalents increased significantly to $6,640,468 as of June 30, 2025, up from $3,325,131 at December 31, 2024, primarily due to financing activities.
• Cash used in operating activities decreased to $1,385,004 for the six months ended June 30, 2025, compared to $2,199,276 for the same period in 2024, mainly due to a non-recurring legal settlement payment in the prior year.
• Research and development expenses for the six months ended June 30, 2025, were $615,186, a slight increase from $596,067 in the comparable 2024 period.
• General and administrative expenses increased to $1,171,377 for the six months ended June 30, 2025, from $1,117,135 in 2024, primarily due to the timing of compensation stock option grants to directors.
• The company successfully completed a public offering on June 27, 2025, raising net proceeds of $4,352,792 from the sale of common stock, pre-funded warrants, and warrants.
• Bone Biologics regained compliance with Nasdaq's minimum bid price rule on June 25, 2025.
• A 1-for-6 reverse stock split of outstanding common stock and warrants became effective on June 10, 2025.
• The company's accumulated deficit reached approximately $86.8 million as of June 30, 2025.
• Operating expenditures for the next twelve months are estimated at $6.8 million, with available cash expected to fund operations into the second quarter of 2026.

Sentiment

Score: 4

Explanation: While the company successfully raised capital and regained Nasdaq compliance, the persistent and increasing net losses, substantial accumulated deficit, and explicit 'going concern' doubt indicate significant financial challenges and high operational risk. The positive cash increase is primarily from financing, not operations, and the company's long-term viability remains highly dependent on future capital raises and successful product development.

Positives

• Cash balance significantly increased to $6.64 million as of June 30, 2025, providing extended liquidity into Q2 2026.
• Successful completion of a public offering on June 27, 2025, raising $4.35 million in net proceeds, demonstrating access to capital markets.
• Regained compliance with Nasdaq's minimum bid price rule, mitigating immediate delisting concerns.
• Progress in the NB1 bone graft device pilot clinical study in Australia, with the first patients treated in 2024, and study design agreed upon by FDA for progression to a pivotal trial.
• Submitted a new patent application with the USPTO in Q2 2025 for rhNELL-1 polypeptide compositions, potentially strengthening intellectual property.

Negatives

• Continued to incur significant net losses, with a net loss of $1,757,611 for the six months ended June 30, 2025.
• Accumulated losses since inception reached approximately $86.8 million, raising substantial doubt about the company's ability to continue as a going concern.
• Reliance on future debt and/or equity financing to fund operations, with no assurance of obtaining sufficient amounts or favorable terms.
• The recent public offering and ATM sales have resulted in substantial dilution for existing stockholders.
• Research and development costs are expected to remain substantial as the company prepares for a pivotal clinical study.

Risks

• Ability to raise additional capital to fund operations and provide working capital.
• Impact of macroeconomic factors such as inflation, rising interest rates, and potential recession.
• Uncertainty in obtaining Food and Drug Administration (FDA) and other regulatory authorization for drug and biological products.
• Risk of encountering problems in clinical trials that could cause delays or suspensions.
• Challenges to patents, invalidation, unenforceability, or circumvention of intellectual property rights.
• Reliance on third-party manufacturers for drug products.
• Uncertainty regarding market acceptance of products.
• Dependence on licenses for certain products, specifically the exclusive license from UCLA TDG.
• Exposure to product liability and defect claims.
• Potential for future financing to contain undue restrictions or cause substantial dilution to stockholders.
• The company's obligation to diligently proceed with developing and commercializing licensed products under UCLA TDG patents, with a risk of license termination or reduction to non-exclusive if diligence milestones are not met.

Future Outlook

The company anticipates continued substantial investment in development activities for NELL-1 as it prepares for a pivotal clinical study in the future. Available cash is expected to fund operations into the second quarter of 2026. The company will continue to seek additional debt and/or equity financing to fund future operations and provide additional working capital, acknowledging no assurance of success or favorable terms.

Management Comments

• Anticipate continued substantial investment in development activities for NELL-1 as we prepare for our pivotal clinical study in the future.
• The decrease in research and development costs for the three months ended June 30, 2025, can be attributed to timing of our clinical trial.
• The increase in general and administrative expenses is primarily attributable to the timing of the issuance of compensation stock options to our directors, which were granted on the date of our annual meeting.

Industry Context

Bone Biologics operates in the highly regulated and capital-intensive medical device and biotechnology sector, specifically focusing on bone regeneration. The development of combination products like NELL-1/DBM requires extensive preclinical and clinical testing and rigorous FDA approval processes, which are common challenges in this industry. The company's reliance on external financing and its 'going concern' status are typical for clinical-stage biotech firms that have not yet commercialized products or generated revenue. The successful capital raise and regaining Nasdaq compliance are positive signs in a competitive market where funding and regulatory hurdles are significant.

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that would individually or in aggregate have a material adverse effect on the business, results of operations, financial condition, or cash flows.

Related Party Transactions

• The company has an Amended and Restated Exclusive License Agreement with UCLA TDG for NELL-1 technology, requiring annual maintenance fees ($10,000), royalties (3.0% of net sales), minimum annual royalties ($50,000-$250,000 after first commercial sale), and milestone payments ($100,000 upon first subject in Feasibility Study, $250,000 upon first subject in Pivotal Study, $500,000 upon Pre-Market Approval, $1,000,000 upon First Commercial Sale).
• A Diligence Fee of $8,000,000 is due to UCLA TDG upon cumulative net sales reaching certain thresholds ($2M at $50M, $2M at $100M, $4M at $200M).
• A cash milestone payment to UCLA TDG is due upon a Liquidity Event (greater of $500,000 or 2% of proceeds from a Change of Control Transaction).
• Payments to UCLA TDG under the license agreement were $17,292 for the six months ended June 30, 2025, and $118,151 for the same period in 2024.

Stakeholder Impact

• Shareholders: Experienced significant dilution from recent public offerings and ATM sales, and a reverse stock split. Face ongoing risk of further dilution from future capital raises.
• Employees/Directors: Benefit from stock-based compensation, with options issued to settle accrued bonuses.
• Creditors: Face risk due to the company's 'going concern' doubt and reliance on future financing.
• UCLA TDG: Continues to receive payments and royalties under the exclusive license agreement, with potential for significant milestone payments upon product commercialization.

Next Steps

• Continue substantial investment in development activities for NELL-1.
• Prepare for a pivotal clinical study for NELL-1/DBM in the United States.
• Attempt to raise additional debt and/or equity financing to fund future operations and provide additional working capital.

Key Dates

Recommendation

Despite a recent capital raise and regaining Nasdaq compliance, Bone Biologics Corporation faces severe financial challenges, including persistent and increasing net losses, a substantial accumulated deficit, and explicit 'going concern' doubt from its auditors. The company's long-term viability is highly dependent on future, uncertain capital raises and successful, lengthy product development and regulatory approval processes. The significant dilution from recent offerings and the inherent risks of a clinical-stage biotech with no revenue generation make this a high-risk investment with a negative outlook.

Keywords

Bone regeneration, Spinal fusion, NELL-1, DBM, Medical device, Biotechnology, Clinical trial, FDA approval, PMA, Public offering, Warrants, Nasdaq compliance, Reverse stock split, Going concern, Biologics